NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Receives Average Recommendation of “Moderate Buy” from Brokerages

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) has been given an average rating of “Moderate Buy” by the five brokerages that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, two have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $8.50.

Separately, Weiss Ratings cut shares of NeuroSense Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 30th.

NeuroSense Therapeutics Stock Up 1.5%

Shares of NRSN stock opened at $0.43 on Tuesday. NeuroSense Therapeutics has a 12-month low of $0.25 and a 12-month high of $1.98. The firm has a market cap of $16.12 million, a P/E ratio of -0.79 and a beta of 1.62. The business has a 50-day moving average price of $0.58 and a two-hundred day moving average price of $0.73.

Insider Transactions at NeuroSense Therapeutics

In related news, CEO Alon Ben-Noon purchased 250,000 shares of NeuroSense Therapeutics stock in a transaction that occurred on Tuesday, June 16th. The shares were bought at an average price of $0.80 per share, for a total transaction of $200,000.00. Following the completion of the transaction, the chief executive officer directly owned 4,534,233 shares of the company’s stock, valued at $3,627,386.40. This represents a 5.84% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Or Eisenberg purchased 250,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 16th. The stock was bought at an average cost of $0.80 per share, with a total value of $200,000.00. Following the completion of the purchase, the chief financial officer owned 1,504,050 shares of the company’s stock, valued at $1,203,240. This represents a 19.94% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders own 27.40% of the company’s stock.

Hedge Funds Weigh In On NeuroSense Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Two Sigma Investments LP bought a new stake in shares of NeuroSense Therapeutics during the 3rd quarter valued at $26,000. Jane Street Group LLC bought a new stake in NeuroSense Therapeutics during the second quarter worth about $54,000. Squarepoint Ops LLC grew its holdings in NeuroSense Therapeutics by 91.0% in the third quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock worth $119,000 after purchasing an additional 45,450 shares during the period. Finally, Yorkville Advisors Global LP bought a new position in shares of NeuroSense Therapeutics during the second quarter valued at approximately $56,160. Hedge funds and other institutional investors own 1.04% of the company’s stock.

About NeuroSense Therapeutics

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.